Ferring Presents Real-World Outcomes Data Analyses for REBYOTA® (fecal microbiota, live – jslm) at IDWeek 2024

Autor:	Ferring Pharmaceuticals
Zdroj:	Business Wire (English). 10/16/2024.
Abstrakt:	Ferring Pharmaceuticals today announced the presentation of two data analyses at IDWeek 2024 evaluating the efficacy and safety of REBYOTA® (fecal microbiota, live – jslm) administered in a real-world setting. REBYOTA is the first and only single-dose microbiome-based therapy approved by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent C. difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for C. diff infection. [ABSTRACT FROM PUBLISHER]
Databáze:	Regional Business News
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.